PILL.CN - Canntab Therapeutics Limited

Canadian Sec - Canadian Sec Delayed Price. Currency in CAD
0.7000
-0.0300 (-4.11%)
At close: 3:32PM EDT
Stock chart is not supported by your current browser
Previous Close0.7300
Open0.7300
Bid0.7000 x 0
Ask0.7500 x 0
Day's Range0.6800 - 0.7300
52 Week Range0.5200 - 2.1400
Volume23,580
Avg. Volume34,112
Market Cap17.715M
Beta (3Y Monthly)-2.79
PE Ratio (TTM)N/A
EPS (TTM)-0.1380
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2016-03-08
1y Target EstN/A
  • CNW Group18 days ago

    Canntab Therapeutics Now Trading on the OTCQX Best Market

    "Historically, it's been difficult for US investors to take ownership of our company, that changes with our upgrade to the OTCQX Best Market. "Ultimately, this is another move along our strategic process with the goal of becoming the global leader of research in, production of and education about our advanced cannabinoid formulations that utilize our patent pending proprietary processes," says Jeff Renwick, co-founder and Chief Executive Officer of Canntab. Canntab is well positioned in the emerging medical cannabis market with 13 patents pending in the United States and Canada covering a range of proprietary processes and formulations.

  • Newsfile25 days ago

    InvestmentPitch Media Video Discusses Canntab Approaching Revenue under FSD Pharma's New "Sale for Medical Purposes" Cannabis License - Video Available on Investmentpitch.com

    Vancouver, British Columbia--(Newsfile Corp. - April 24, 2019) - Canntab Therapeutics (CSE: PILL) (OTCQB: CTABF) (FSE: TBF1), a Canadian cannabis oral dosage formulation company, engaged in the research and development of advanced pharmaceutical grade formulations of cannabinoids, has advanced its revenue model following FSD Pharma's receipt of a "Sale for Medical Purposes" license. By virtue of Canntab's collaboration and profit sharing agreement with FSD Pharma (CSE:HUGE), this new license allows Canntab to produce ...

  • CNW Group26 days ago

    Canntab Advances its Revenue Model with Recent Sales License Approval for FSD Pharma from Health Canada

    TORONTO, April 23, 2019 /CNW/ - Canntab Therapeutics Limited (CSE:PILL.CN - News) (OTCQB:CTABF - News) (FRA:TBF1.F - News) (the "Company" or "Canntab") is pleased to announce that by virtue of FSD Pharma Inc. ("FSD"), with whom Canntab has entered into a collaboration and profit sharing agreement, being granted a "sale for medical purposes" licence by Health Canada pursuant to the Cannabis Act and Cannabis Regulations (the "FSD Licence"), Canntab is close to being in a position to sell its products and generate revenue. The FSD Licence allows Canntab to produce samples of capsules containing CBD and/or THC, which, if approved by Health Canada, will enable Canntab to launch production and sales out of its manufacturing facility located in Room 6 of FSD's Health Canada approved facility in Cobourg, Ontario.

  • Newsfile27 days ago

    FSD Pharma Receives Cannabis Sales License from Health Canada

    \- New license positions FSD to serve the growing medicinal use markets - Toronto, Ontario--(Newsfile Corp. - April 22, 2019) - FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) ("FSD" or the "Company"), announced today that its wholly-owned subsidiary FV Pharma Inc. has received its Sale for Medical Purposes license to sell cannabis under the Cannabis Act (Canada). The license went into effect on April 18, 2019.The license allows the current FSD facility ...

  • GlobeNewswire2 months ago

    Canntab Therapeutics Announces Engagement of Relations Publiques Paradox Inc. for Investor Relations Services

    Canntab Therapeutics Limited (CSE:PILL) (the “Company” or “Canntab”) is pleased to announce that, effective March 21, 2019, it has engaged Relations Publiques Paradox Inc. (“Paradox”) to provide investor relations services to the Company. Paradox is a Montreal based investor relations consultancy firm that has been in business for 20 years, and is led by entrepreneur, Jean-Francois Meilleur. Paradox has represented a number of public companies through its extensive network and experience in the capital markets.

  • GlobeNewswire3 months ago

    Canntab Enters into Five Year Supply and Loan Agreement with FSD Pharma and World Class Extractions on Organic Hemp Deal

    Canntab Therapeutics Limited (CSE: PILL, OTCQB: CTABF, FSE: TBF1) (“Canntab” or the “Company”) is pleased to announce that it has entered into a supply and loan agreement (the “Agreement”) with FSD Pharma Inc. (“FSD”) and World Class Extractions Inc. (“World Class”) (collectively, the “Purchasers”) to purchase hemp flower from Thomas Elcome (the “Supplier”). Pursuant to the Agreement, the Supplier grants the Purchasers the right and option to purchase up to CAD $5.0 million of the Supplier’s hemp crop for a period of 5 years commencing in 2019 at a purchase price of CAD $100.0 per kg per 1% of CBD extracted from the flower.

  • GlobeNewswire3 months ago

    Canntab Provides Corporate Update

    Moving into FSD Pharma and FSD Processing LicenseMackie Research ExtensionDirector Estate Planning InitiativeOTCQB under symbol CTABF TORONTO, Feb. 19, 2019 -- Canntab.

  • GlobeNewswire3 months ago

    Canntab Enters into Supply Agreement with FSD Pharma and World Class Extractions on Organic Hemp Deal

    Canntab Therapeutics Limited (CSE: PILL, FSE: TBF1) (“Canntab”), a leader in the development of precision oral dose cannabis tablets and capsules, announced today that it has entered into a supply agreement (the “Agreement”) with FSD Pharma Inc. (“FSD Pharma”) and World Class Extractions Inc. (“World Class”) (the “Purchasers”) to purchase hemp flower from Thomas Elcome (the “Supplier”). Pursuant to the agreement, the Purchasers have agreed to buy approximately 1,000 kg of the Supplier’s 2018 hemp crop at a purchase price of $100.00 per kg per 1% of CBD extracted from the flower.

  • GlobeNewswire4 months ago

    FSD Pharma & Canntab Rank Among the Top 2018 Cannabis Stocks -- CFN Media

    SEATTLE, Jan. 17, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article discussing FSD Pharma Inc’s. (CSE:HUGE) (FSDDF) (0K9.F) & Canntab Therapeutics Ltd’s. (CSE:PILL) (TBF1.F) performance in 2018. The cannabis industry experienced significant growth last year, particularly in Canada following the legalization of adult-use cannabis on a federal level. The upcoming legalization of edible products across Canada could open the door to further growth in 2019 and beyond.

  • GlobeNewswire5 months ago

    Canntab & FSD Pharma Make Cannabis More Palatable for Doctors -- CFN Media

    SEATTLE, Dec. 21, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article discussing Canntab Therapeutics Ltd. (CSE:PILL) (TBF1.F). The company is an emerging leader in solid oral dosage cannabis formulations, which are designed to make cannabinoid dosing more accurate and reliable. With 13 patents pending in the United States and Canada, the company is developing instant release, extended release, flash melt, and bi-layer tablets available in 2.5mg, 5mg, and 10mg formulations to ease these concerns.

  • GlobeNewswire5 months ago

    Canntab Partners with Leading Surgeon to Conduct Pain Management Trial -- CFN Media

    SEATTLE, Dec. 13, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article discussing Canntab Therapeutics Ltd. (CSE:PILL) (TBF1.F), The company recently announced a partnership with world-renowned orthopaedic surgeon, Dr. Don Garbuz, MD, to conduct a clinical trial to analyze the efficacy of cannabis as a replacement for opioids in postoperative care. The opioid industry is expected to generate nearly $20 billion in annual revenue by 2020, but the addictive nature of the drug has doctors and patients increasingly concerned. With the legalization of cannabis across Canada and many U.S. states, there’s an opportunity to replace dangerous opioids with efficacious cannabinoids to treat chronic and acute pain.

  • GlobeNewswire5 months ago

    Canntab Enters Into a Binding Term Sheet With Leading Orthopaedic Surgeon Dr. Don Garbuz, M.D. for a Clinical Research Trial of Canntab’s Tablets

    Partnership formed with Dr. Don Garbuz, an award winning orthopaedic surgeon and medical researcher, credited with over 120 peer reviewed publications. The parties will seek to conduct a clinical study with orthopaedic patients, using Canntab’s sustained release tablets. The study will also seek to show the efficacy of Canntab’s cannabis products for pain management and improvements in patient overall health outcomes.

  • GlobeNewswire6 months ago

    Canntab Nears Commercialization with Innovative Cannabis Tablets-- CFN Media

    SEATTLE, Nov. 29, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article discussing a key problem facing the medical cannabis industry: dosing and consistency. Unlike pharmaceuticals, medical cannabis is typically prescribed in a smokable form that can produce inconsistent effects between patients. Many pharmaceuticals also offer extended release and features that can make the medicine more efficacious.

  • GlobeNewswire6 months ago

    Canntab Announces Correction to Press Release 

    NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE U.S. TORONTO, Nov. 14, 2018 -- Canntab Therapeutics Limited (CSE: PILL, FSE: TBF1) (“Canntab” or.

  • GlobeNewswire6 months ago

    Canntab Corporate Update

    Canntab Therapeutics Limited (CSE: PILL, FSE: TBF1) (“Canntab” or the “Company”) is a company with a clear vision of becoming the leader in solid oral dosage formulation of cannabis.  Their unique products offer advantages to the medical community, patients, adult use consumers and governments.  Canntab is pleased to provide this corporate update to its shareholders. A strong intellectual property portfolio with 13 patents pending in the United States and Canada pertaining to the formulation of tablets including instant release, extended release, flash melt and bi-layered. An application to become a Licensed Producer (Non Grower) under the Access to Cannabis for Medical Purposes Regulations and has confirmation from Health Canada that its application had been received.

  • GlobeNewswire7 months ago

    Canntab to Enter Medicinal Cannabis Market in Mexico

    Canntab Therapeutics Limited (CSE: PILL, FSE: TBF1) (“Canntab” or the “Company”) today announced the signing of a non-binding Letter of Intent (the “LOI”) with Labsco Promedic SA de CV of Monterrey, Mexico (“Labsco”) for the establishment of a joint venture relationship for the sales & distribution of Canntab products in Mexico (the “Territory”) on an exclusive basis. Following the LOI, the parties will work together to establish and complete a formal joint venture relationship for an initial period of five years.

  • Newsfile7 months ago

    InvestmentPitch Media Video Discusses Canntab Therapeutics and its Application to Become a Licensed Producer Under ACMPR with Health Canada - Video News Alert on Investmentpitch.com

    Vancouver, British Columbia--(Newsfile Corp. - October 22, 2018) -  Canntab Therapeutics (CSE: PILL) (FSE: TBF1), a Canadian cannabis oral dosage formulation company, engaged in the research and development of advanced pharmaceutical grade formulations of cannabinoids, has filed an application to become a Licensed Producer under the Access to Cannabis for Medical Purposes Regulations with Health Canada. The License, if granted by Health Canada, would allow the company to process cannabis products at its current ...

  • Newsfile7 months ago

    Canntab Files Application to Become Licensed Producer

    Toronto, Ontario--(Newsfile Corp. - October 18, 2018) - Canntab Therapeutics Limited (CSE: PILL) ("Canntab" or the "Company") a leader in the development of precision oral dose cannabis tablets and capsules, is pleased to announce that it has filed an application to become a Licensed Producer under the Access to Cannabis for Medical Purposes Regulations (the "License"), and that it received confirmation from Health Canada that its application had been received. The License, ...

  • Newsfile7 months ago

    Canntab Therapeutics, Extended Release Cannabis Tablets, CEO Clip Video

    Vancouver, British Columbia--(Newsfile Corp. - October 4, 2018) - Jeff Renwick, CEO of Canntab Therapeutics speaks about their proprietary solid cannabis delivery system technology. If you cannot view the video above, please visit:https://www.b-tv.com/canntab-therapeutics-ceo-clip-90sec/Canntab Therapeutics is being featured on BNN Bloomberg on Oct. 13 — Oct. 14, 2018 Monday through Friday, throughout the day and evenings.Canntab Therapeutics (CSE: PILL)canntab.caAbout CEO Clips:CEO Clips is the largest library of publicly traded company CEO videos in ...

  • Newsfile7 months ago

    InvestmentPitch Media Video Discusses Canntab Therapeutics LOI With NewCanna of Colombia to Distribute Canntab Products in Select Countries - Video News Alert on Investmentpitch.com

    Vancouver, British Columbia--(Newsfile Corp. - October 4, 2018) -  Canntab Therapeutics (CSE: PILL) (FSE: TBF1), a Canadian cannabis oral dosage formulation company, engaged in the research and development of advanced pharmaceutical grade formulations of cannabinoids, has Signed a non-binding Letter of Intent with NewCanna S.A.S. of Bogota, Colombia, The LOI establishes a significant bi-lateral relationship granting NewCanna the right to sell and distribute certain Canntab exclusive proprietary products, and the right to utilize Canntab's ...

  • Newsfile8 months ago

    Canntab Enters LOI for Bi-Lateral Sales & Distribution and Cannabis Oil Supply

    Toronto, Ontario--(Newsfile Corp. - October 1, 2018) - Canntab Therapeutics Limited (CSE: PILL) (FSE: TBF1) ("Canntab" or the "Company"), today announced the completion of a non-binding Letter of Intent (the "LOI") with NewCanna S.A.S of Bogota, Colombia ("NewCanna") for the establishment of a significant bi-lateral relationship for the sale & distribution of Canntab's products. The territory applicable to the agreement is the countries of Colombia, Chile, Paraguay and Spain, (collectively, the "Territory"). The ...

  • Newsfile8 months ago

    FSD Pharma Receives First Delivery of Canntab Equipment with a Capacity to Manufacture Approx. 1,500,000 Tablets per Day

    Toronto, Ontario--(Newsfile Corp. - September 25, 2018) - FSD Pharma Inc. (CSE: HUGE) (OTC: FSDDF) (FSE: 0K9) ("FSD Pharma" or the "Company), which, through its wholly-owned subsidiary FV Pharma Inc., is a licensed producer pursuant to the Access to Cannabis for Medical Purposes Regulations, is pleased to announce that the Company has received its first delivery of manufacturing equipment at its Cobourg plant from Canntab Therapeutics Limited (CSE: PILL) ("Canntab"), a leader in ...

  • Newsfile8 months ago

    Canntab Added to CSE Composite Index

    Toronto, Ontario--(Newsfile Corp. - September 24, 2018) - Canntab Therapeutics Limited (CSE: PILL) (FSE: TBF1) ("Canntab" or the "Company"), is pleased to inform investors that effective September 21, 2018 the Company has been added to the Composite Index of the Canadian Securities Exchange as part of the CSE's quarterly rebalancing.Based on the September 21 closing price of PILL, the Company's market capitalization is above the average market cap of the Index component companies and ...

  • Newsfile8 months ago

    Canntab Sets New All-Time High Trading Prices and Volume

    Toronto, Ontario--(Newsfile Corp. - September 20, 2018) - Canntab Therapeutics Limited (CSE: PILL) ("Canntab" or the "Company"), a leader in the development of the cannabis in tablet or capsule form, is pleased to announce that the Company's common shares ("Common Shares") yesterday reached new all-time daily high and closing prices of $1.74 and $1.41, respectively, on the Canadian Securities Exchange (the "CSE"). These numbers exceed the Company's previous all-time highs by 39.2% and 15.6%, ...